Congenital Varicella Syndrome

Overview

• Definition: Congenital Varicella Syndrome (CVS) is a rare but severe constellation of fetal anomalies resulting from maternal primary varicella zoster virus (VZV) infection during pregnancy, typically in the first 20 weeks of gestation. It is characterized by skin lesions, limb hypoplasia, neurological abnormalities, and ocular defects.
• Epidemiology: The incidence of maternal primary varicella infection during pregnancy is approximately 0.7 to 7 per 1,000 pregnancies. The risk of CVS following primary maternal VZV infection is estimated to be 0.4% to 2% when infection occurs before 13 weeks of gestation, and 2% if infection occurs between 13 and 20 weeks of gestation. If maternal infection occurs after 20 weeks gestation, the risk of CVS is extremely low.
• Classification: While not formally classified into types, the clinical manifestations of CVS vary in severity and combination, directly correlating with the timing and extent of intrauterine viral damage.

Pathophysiology

• Mechanism: Primary maternal VZV infection during pregnancy leads to viremia, allowing the virus to cross the placenta and infect the fetus. VZV is a neurotropic and dermatotropic virus. Fetal infection results in vasculitis, particularly affecting the ganglionic and axonal cells, leading to ischemic necrosis, atrophy, and scar formation in developing tissues. The virus establishes latency in dorsal root ganglia and autonomic ganglia, leading to chronic inflammation and tissue damage. The precise mechanism by which the timing of infection correlates with specific anomalies (e.g., limb hypoplasia) is not fully understood but is thought to involve critical periods of organogenesis.
• Risk Factors:
  • Primary maternal VZV infection: The critical prerequisite. Maternal history of chickenpox or vaccination confers protective immunity.
  • Timing of infection: Greatest risk for fetal abnormalities is with maternal infection during the first 20 weeks of gestation, particularly 8-20 weeks.
• Protective Factors:
  • Maternal immunity: Prior varicella infection or vaccination (two doses of varicella vaccine) before pregnancy confers protective antibodies, preventing primary infection.
  • Varicella-zoster immune globulin (VZIG): Prophylactic administration to susceptible pregnant women following VZV exposure can prevent or attenuate maternal infection, thereby reducing fetal risk.

Clinical Presentation

Signs and Symptoms

• Cardinal Features:
  • Cutaneous cicatricial lesions: Scarring skin lesions, often in a dermatomal distribution, can be extensive and lead to tissue loss. These are hallmark findings.
  • Limb hypoplasia: Underdevelopment or shortening of an affected limb (usually unilateral), often associated with muscular atrophy and bony defects.
  • Ocular defects: Chorioretinitis (leading to blindness), microphthalmia, cataracts, nystagmus, optic atrophy, Horner's syndrome.
  • Neurological abnormalities: Microcephaly, cortical atrophy, intellectual disability, seizures, cerebellar hypoplasia, autonomic dysfunction (e.g., swallowing difficulties, neurogenic bladder).
• Early Signs (in utero): Detected via prenatal ultrasound: limb deformities, microcephaly, hydrops fetalis, intrauterine growth restriction (IUGR), echogenic bowel, ascites.
• Advanced Signs (postnatal): Manifestations at birth or in early infancy if not detected prenatally. May include severe developmental delay, profound intellectual disability, intractable seizures, and significant motor impairment.
• Atypical Presentations: Mild cases may present with only one or two isolated findings. Some infants may present solely with a zoster-like eruption in infancy in the absence of other typical CVS features, believed to be due to residual virus from an in utero infection.

Physical Examination

• Inspection:
  • Skin: Linear, zig-zag, or punched-out cicatricial scars, often hypopigmented, with a dermatomal pattern. Can be associated with hair loss or telangiectasias.
  • Limbs: Significant shortening and circumference reduction of one or more limbs, clubfoot, equinovarus deformity, muscular atrophy, absent digits or phalanges.
  • Eyes: Microphthalmia, cataracts, corneal opacities, nystagmus, strabismus, ptosis.
  • Head: Microcephaly.
  • Trunk: Spinal abnormalities (scoliosis), abdominal distension.
• Palpation: Assess muscle tone, joint mobility, and skeletal deformities.
• Special Tests:
  • Neurological examination: Assess primitive reflexes, muscle tone, cranial nerve function, and developmental milestones in infants. Look for signs of autonomic dysfunction (e.g., poor feeding, aspiration).
  • Ophthalmological examination: Full dilated funduscopic exam to detect chorioretinitis and optic atrophy.
  • Audiological evaluation: Brainstem auditory evoked responses (BAER) to assess hearing due to potential sensorineural hearing loss.

Diagnostic Approach

History Taking

• Key Questions:
  • Maternal history of primary VZV infection during pregnancy: Date of exposure, date of rash onset, typical vesicular rash, constitutional symptoms.
  • Maternal vaccination status and history of chickenpox: Confirms immune status.
  • Exposure history: Contact with individuals with chickenpox or shingles during pregnancy.
  • Prenatal screening results: Any abnormalities noted on routine ultrasound.
  • Family history: Other congenital anomalies.
• Red Flags:
  • Maternal primary VZV infection during the first 20 weeks of gestation, especially 8-20 weeks.
  • Detection of fetal abnormalities on prenatal ultrasound (e.g., IUGR, microcephaly, limb defects).

Laboratory Tests

• First-Line:
  • Maternal serology: Confirm primary maternal VZV infection: VZV IgM positive and VZV IgG seroconversion (or low/negative VZV IgG with positive VZV IgM).
  • Amniocentesis: If maternal infection occurred before 20 weeks and fetal abnormalities are suspected or to assess fetal infection status. Detect VZV DNA by PCR in amniotic fluid. A positive PCR indicates fetal infection but does not predict severity.
• Confirmatory:
  • VZV DNA PCR from fetal tissue: (e.g., skin biopsy from affected lesions, umbilical cord blood) post-natally, if diagnosis is uncertain.
  • Histopathology of affected lesions: May show vasculitis and necrosis.
• Monitoring:
  • Newborn VZV IgG/IgM: To confirm fetal infection.
  • Viral culture: Rarely positive from neonates with CVS.

Imaging

• Recommended:
  • Prenatal ultrasound: Serial detailed ultrasounds are crucial for detecting fetal anomalies. Look for microcephaly, limb shortening, IUGR, hydrops, hyperechogenic bowel, cardiac defects, hydronephrosis. Can become apparent weeks to months after maternal infection.
  • Fetal MRI: May provide more detailed information on brain morphology (cortical atrophy, ventricular enlargement, white matter abnormalities) when abnormalities are suspected on ultrasound.
  • Postnatal MRI (brain): To delineate structural brain anomalies (e.g., microcephaly, cortical atrophy, cerebellar hypoplasia, encephalomalacia).
  • Skeletal radiographs: To evaluate limb hypoplasia, bone deformities, and vertebral anomalies.
• Advanced:
  • Fetal echocardiography: If cardiac anomalies are suspected.

Management

Acute Management (Postnatal)

• Immediate:
  • Stabilization: For neonates with severe manifestations (e.g., respiratory distress from aspiration, seizures).
  • Supportive care: Respiratory support, nutritional support, hydration.
• Stabilization:
  • Antiviral therapy: IV acyclovir (10-20 mg/kg/dose every 8 hours) is generally not indicated for neonates with established CVS as the damage is done. It may be considered in cases of disseminated neonatal VZV infection (which is distinct from CVS and occurs with maternal infection in the peripartum period), but this is not CVS.
  • Symptomatic treatment: Pain management for severe skin lesions, anti-epileptic drugs for seizures.
• Emergency:
  • Resuscitation: For neonates with severe birth depression or critical organ dysfunction.

Chronic Management

• Pharmacological:
  • Antiepileptic drugs: For seizure control.
  • Botulinum toxin: For management of severe muscle contractures or spasticity.
  • Medications for neurogenic bladder: (e.g., anticholinergics).
• Non-pharmacological:
  • Multidisciplinary approach: Essential, involving neonatologists, neurologists, ophthalmologists, orthopedic surgeons, physical therapists, occupational therapists, speech therapists, developmental pediatricians, and social workers.
  • Physical and occupational therapy: To maximize function, manage contractures, and aid in motor development.
  • Speech therapy: For feeding difficulties, dysphagia, and communication development.
  • Special education: For developmental delays and intellectual disabilities.
  • Orthopedic interventions: Splinting, bracing, surgical correction for limb deformities (e.g., clubfoot correction, limb lengthening procedures, tendon releases).
  • Ophthalmological interventions: Cataract removal, correction of strabismus, low vision aids.
  • Psychological support: For families.
• Monitoring:
  • Regular developmental assessments: To track progress and identify new needs.
  • Neurological follow-up: For seizure control and neurodevelopmental surveillance.
  • Ophthalmological follow-up: To monitor vision and manage complications of chorioretinitis.
  • Orthopedic follow-up: To address progressive skeletal deformities.
  • Audiological screening: Repeat testing as needed.

Treatment Algorithms

• First-Line: Supportive care and multidisciplinary symptomatic management.
• Second-Line: Surgical interventions for significant deformities or functional impairments.
• Refractory Cases: Management revolves around optimizing quality of life through comprehensive rehabilitation, specialized equipment, and ongoing medical oversight for complex symptoms (e.g., refractory epilepsy, profound developmental impairment, severe feeding difficulties requiring gastrostomy tube).

Complications

• Common: Developmental delay, intellectual disability, seizures, vision impairment (ranging from poor acuity to blindness), limb contractures, chronic pain from neurogenic damage/scarring.
• Serious: Severe neurological impairment leading to dependence, intractable seizures, aspiration pneumonia, profound limb dysfunction impacting mobility. Recurrent herpes zoster (shingles) in early childhood is also a recognized complication due to the presence of latent VZV from the primary infection.
• Long-term: Chronic physical disabilities, lifelong dependency, educational and social integration challenges, increased risk of early mortality in severely affected individuals.

Prognosis

• Factors: Severity of malformations, particularly neurological involvement, is the primary determinant of prognosis. The earlier the maternal infection and the more severe the fetal manifestations seen prenatally, the poorer the prognosis.
• Survival: Mortality rates are high, with studies reporting 25-30% mortality in the neonatal period or early infancy, primarily due to overwhelming neurological involvement, widespread organ damage, or infection.
• Quality of Life: Survivors often face significant lifelong physical and intellectual disabilities, requiring comprehensive medical, rehabilitative, and educational support. Many require lifelong care.

Prevention

Primary

• Maternal immunization:
  • Pre-conception: All women of childbearing age should be screened for VZV immunity. Those without immunity (no history of chickenpox or vaccination) should be offered two doses of varicella vaccine (live attenuated) at least one month apart, ideally 3 months before conception. Pregnancy should be avoided for 1 month after receiving each dose of the vaccine (CDC).
  • Post-exposure prophylaxis (PEP): For VZV-susceptible pregnant women exposed to VZV (chickenpox or shingles contact). Administer Varicella-Zoster Immune Globulin (VZIG) within 96 hours (up to 10 days in some guidelines) of exposure. VZIG can prevent or attenuate maternal infection, significantly reducing the risk of fetal transmission and CVS. The dosage for VZIG (VariZIG in the US) is 125 units/10 kg body weight, up to a maximum of 625 units, administered intramuscularly.
• Avoidance of exposure: Susceptible pregnant women should avoid contact with individuals with active chickenpox or shingles.

Secondary

• Early detection and intervention:
  • Prompt diagnosis of maternal infection: If suspected, confirm with VZV serology.
  • Referral to maternal-fetal medicine specialists: For detailed prenatal assessment following maternal VZV infection.
  • Serial detailed fetal ultrasounds: To monitor for the development of fetal anomalies.
  • Amniocentesis: May be offered to confirm fetal infection if anomalies are suspected or for parental reassurance/counseling, though a positive PCR does not predict severity.
  • Patient counseling: Comprehensive discussion with parents regarding potential risks, prognosis, and available management options, including termination of pregnancy where legally permissible.

Tertiary

• Preventing complications:
  • Early multidisciplinary intervention: As outlined in chronic management to mitigate long-term disability and maximize functional outcomes.
  • Genetic counseling: For future pregnancies.

Special Populations

• Pediatric: This condition primarily affects neonates and children. Management focuses on neurodevelopmental support, rehabilitation, and addressing specific organ system dysfunction throughout childhood.
• Geriatric: Not applicable as CVS is a congenital condition.
• Pregnancy: Prevention (vaccination, PEP with VZIG) and prenatal diagnosis are critical aspects of pregnancy management for VZV-susceptible women.
• Comorbidities: Management is tailored to the specific comorbidities present (e.g., congenital heart defects, renal anomalies, pulmonary issues), requiring coordination among multiple subspecialists.

Clinical Pearls

• Diagnostic: The classic triad of skin scarring, limb hypoplasia, and ocular defects, combined with a history of primary maternal VZV infection in early pregnancy, is highly suggestive of CVS. Always inquire about maternal past medical history (chickenpox, vaccination).
• Treatment: While there is no cure for CVS, aggressive symptomatic and supportive care by a multidisciplinary team can significantly improve the quality of life for affected individuals. Do not expect antiviral agents to reverse established damage.
• Pitfalls: Misattributing skin lesions of CVS to mechanical trauma or other dermatological conditions. Failing to obtain a detailed maternal history of VZV exposure or infection during pregnancy. Underestimating the long-term impact on neurodevelopment and quality of life. Incorrectly diagnosing CVS in cases of neonatal varicella (maternal infection 5 days before to 2 days after delivery), which presents with active vesicular lesions and can be treated with acyclovir.

Recent Updates

• Guidelines: The American College of Obstetricians and Gynecologists (ACOG) and the Centers for Disease Control and Prevention (CDC) continue to emphasize pre-conception VZV immunity screening and vaccination for women of childbearing age, and prompt administration of VZIG (VariZIG) for susceptible pregnant women exposed to VZV.
• Evidence: Research continues to refine the understanding of VZV pathogenesis and the precise mechanisms of fetal damage. Improved imaging modalities (e.g., fetal MRI) allow for earlier and more detailed prenatal diagnosis of fetal anomalies.
• Controversies: The utility of antiviral therapy for the mother during primary VZV infection has been debated; while it may reduce the severity or duration of maternal illness, its impact on preventing fetal infection or mitigating the severity of CVS is not definitively established. The role of routine non-invasive prenatal testing (NIPT) or cell-free DNA for VZV detection is not yet standard but is an area of ongoing research.

Key References

• Guidelines:
  • American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin No. 200: Management of Varicella in Pregnancy. (2018)
  • Centers for Disease Control and Prevention (CDC) Recommendations of the Advisory Committee on Immunization Practices (ACIP): Prevention of Varicella. (2007) (Updated periodically on the CDC website)
• Studies:
  • Enders, G. et al. (1994). Consequences of varicella and herpes zoster in pregnancy: Prospective study of 1739 pregnancies. Lancet, 343(8912), 1547-1550.
  • Pastuszak, A. L. et al. (1994). Outcome after maternal varicella infection in the first 20 weeks of pregnancy. New England Journal of Medicine, 330(15), 901-905.
• Reviews:
  • Cohen, J. I., Breuer, J., KuCCia, N. L., & Oxman, M. N. (2019). Varicella-Zoster Virus Infection. In Harrison's Principles of Internal Medicine (20th ed.). McGraw-Hill Education.
  • Paya, C. V., & Smith, T. F. (2006). Congenital Varicella Syndrome. In Infectious Diseases of the Fetus and Newborn Infant (6th ed.). Elsevier Saunders.

---

Disclaimer: This information is provided for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. It is intended for healthcare professionals and should not be used as a substitute for professional medical judgment. Always consult with a qualified healthcare provider for any health concerns or before making any decisions related to patient care. Clinical judgment remains paramount in every patient encounter.